Patent medicine the patent medicines, some of their makers began replacing the opium tincture laudanum with acetanilide, a particularly toxic non-steroidal anti-inflammatory drug with analgesic as well as antipyretic properties that had been introduced into medical practice under the name "Antifebrin" by A. Cahn and P. Hepp in 1886. But this ingredient change probably killed more of the nostrum's users than the original narcotics did, since acetanilide not only caused an alarming cyanosis due to methemoglobinemia but was later discovered to cause liver and kidney damage. The occasional reports of acetanilide-induced cyanosis prompted the search for supposedly less toxic aniline derivatives, such
Experimental drug in the European Union (EU) are regulated by the European Medicines Agency (EMA). Beginning in 2019 all applications for clinical trials must use a centralize EU portal and database. All clinical trial results will available to the public with the summary written in layperson's language. Experimental drug An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions. In